Recent activity
Why this organization matters now
Dated Jun 15, 2026
On June 15, 2026, CCRM, OmniaBio, and Avectas announced an evaluation agreement concerning cell-engineering and manufacturing technology.
Source: OmniaBio independent program, contract or operating evidence (opens in a new tab)Technologies and services
A closer look at the products, services, operating features, and documented applications that shape the organization’s role.
Source-bounded strategic technology capability
Intelligent Factory cell-and-gene-therapy manufacturing
What it enables
OmniaBio provides process development and GMP manufacturing services for cell and gene therapies while developing automation, robotics, analytics, and digital controls for manufacturing workflows. Planned intelligent-factory capabilities should be separated from currently validated GMP operations.
Evidence strength: ModerateLast reviewed Aug 12, 2026
Operating context
Maturity
Innovation, Science and Economic Development Canada's public evidence confirms a company-specific project, award, program or operating context, while configuration-specific acceptance and scale remain bounded by the reviewer warning.
Availability
OmniaBio currently presents Intelligent Factory cell-and-gene-therapy manufacturing through its official public capability surface.
Decision-useful features
- GMP cell-and-gene-therapy process and manufacturing services
- Automation, robotics, and digital manufacturing controls
Technical detail and applications
Documented applications. Domestic advanced-therapy manufacturing capacity · Scale-up and technology transfer for cell therapies
Prepare the conversation
Questions for a first conversation
Which current configurations and independently accepted outcomes best define OmniaBio's Intelligent Factory cell-and-gene-therapy manufacturing readiness?
Distinguish OmniaBio from parent CCRM and separate operating GMP services from planned automation; performance and capacity claims require program-level verification. The first conversation should therefore separate current offer, development evidence and accepted operational use.
Geography
Hamilton, Ontario
The map is centred on Hamilton. It does not imply a street address or exact facility location.
Open in the ecosystem mapSource library
Sources behind this profile
Open the original record, then expand the source details to see which parts of the dossier it informs.
Public sources cited · Facts and assessments kept separate · Human review
Public sources
3
Last reviewed
Aug 12, 2026
Identity and profile
- Open source: OmniaBio independent program, contract or operating evidence
OmniaBio independent program, contract or operating evidence
Innovation, Science and Economic Development Canada · Jun 15, 2026
Move into a better-informed conversation
Take this dossier into the next conversation.
Save the organization and its public record in a private Shortlist, then request a human-routed introduction when the fit is specific enough to discuss.